What did @calxshreds actually say?
The creator answered a viewer question about whether 300mg/week of testosterone with enclomiphene is safe for a first cycle. Their core argument: PCT is "stupid and outdated," first cycles should be treated as potentially lifelong commitments, and HCG at "750 IU per week, 250 IU per week" is a better option than enclomiphene for preserving testicular function on cycle. They also plugged a source called "ROHM" for obtaining HCG.
A few things to unpack here. The creator conflates enclomiphene (a selective estrogen receptor modulator, or SERM) with something to avoid, while positioning HCG as the cleaner alternative. They also frame a 300mg weekly testosterone dose, which is a supraphysiologic bodybuilding dose, as something close to a reasonable TRT starting point. That framing deserves scrutiny.
Does the science back this up?
Partially. The core physiology around HCG is accurate, but several clinical details are either garbled or missing entirely.
HCG does mimic luteinizing hormone (LH). When exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, intratesticular testosterone drops sharply even if serum testosterone is high. Coviello et al. (2005, Journal of Clinical Endocrinology and Metabolism) confirmed that HCG co-administration during exogenous testosterone use preserves intratesticular testosterone and maintains testicular volume. That part the creator got right.
The claim that enclomiphene is a SERM that acts at the hypothalamus is also broadly correct. Wiehle et al. (2014, Andrology) showed enclomiphene raises LH and FSH through hypothalamic estrogen receptor blockade. However, the assertion that it causes "nasty issues" is vague, unsubstantiated in this context, and appears to serve a product recommendation more than a clinical argument. Enclomiphene is actively studied as a fertility-preserving alternative to TRT precisely because it maintains the HPG axis. Dismissing it without evidence is not balanced advice.
What did they get wrong (or right)?
They got the HCG mechanism right. They got the enclomiphene mechanism mostly right. Everything else is shakier.
- The dose numbers are contradictory. The creator says "750 IU per week, 250 IU per week" in the same breath. These are two different protocols and conflating them without context creates confusion. Standard clinical HCG co-administration in TRT literature typically uses 250-500 IU administered two to three times per week (Ramasamy et al., 2015, Fertility and Sterility). No single universally correct dose exists, and presenting numbers without that context is irresponsible.
- "PCT is stupid and outdated" is an opinion dressed as fact. Recovery of the HPG axis after cessation is real and documented. Turek et al. have published on successful axis recovery after steroid cycles, particularly in younger men with shorter exposure. PCT outcomes vary enormously by individual, cycle length, and compounds used.
- Framing 300mg/week as a "first cycle" starting point is problematic. Physiologic TRT doses are typically 100-200mg/week. Recommending 300mg to an audience that may include people with no medical oversight is not responsible harm reduction.
- Directing viewers to purchase HCG from a commercial chat source is a regulatory red flag. HCG is a prescription medication in most jurisdictions. Sourcing it outside licensed pharmacy channels is both legally questionable and medically unsafe.
What should you actually know?
The underlying question, whether HCG or enclomiphene better preserves testicular function during exogenous androgen use, is a legitimate clinical question. The answer is not as simple as this video implies.
HCG directly stimulates Leydig cells via LH receptor binding, which maintains intratesticular testosterone and sperm production. This is well-supported. Enclomiphene works upstream by blocking hypothalamic estrogen receptors, increasing endogenous LH and FSH, which only helps if the testicular machinery is still responsive. During heavy exogenous androgen use, the upstream approach may be less effective because suppression is already occurring at multiple levels. In that specific context, HCG has more direct evidence.
But "enclomiphene causes nasty issues" without citation is not a clinical argument. It is a sales pitch. Enclomiphene's side effect profile in clinical trials has generally been mild, including headache and visual disturbances at higher doses, similar to other SERMs. Wiehle et al. (2014) reported no serious adverse events at therapeutic doses.
Anyone considering hormone management, whether for TRT, fertility, or performance purposes, should be doing this with a physician who can monitor labs, not based on a 90-second TikTok tied to a product link.